User:Mr. Ibrahem/Capmatinib
 | |
| Clinical data | |
|---|---|
| Trade names | Tabrecta |
| Other names | INC280 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620038 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase inhibitor[1] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C23H17FN6O |
| Molar mass | 412.428 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Capmatinib, sold under the brand name Tabrecta, is a medication used to treat non-small cell lung cancer (NSCLC).[2] Specifically it is used for metastatic disease with MET exon 14 skipping.[2] This is found in 3-4% of people with lung cancer.[3] It is taken by mouth.[2]
Common side effects include peripheral swelling, nausea, tiredness, shortness of breath, and decreased appetite.[2] Other side effects may include pneumonitis, liver problems, and sunburns.[2] Use during pregnancy may harm the baby.[2] It is a tyrosine kinase inhibitor.[1]
Capmatinib was approved for medical use in the United States in 2020.[1] It is not approved in Europe or the United Kingdom as of 2021.[4] In the United States 4 weeks costs about 19,800 USD as of 2021.[5]
References[edit]
- ^ a b c "Capmatinib Monograph for Professionals". Drugs.com. Retrieved 29 December 2021.
- ^ a b c d e f g h i j "Tabrecta- capmatinib tablet, film coated". DailyMed. 6 May 2020. Archived from the original on 8 May 2020. Retrieved 8 May 2020.
- ^ "FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer". U.S. Food and Drug Administration (FDA) (Press release). 6 May 2020. Archived from the original on 7 May 2020. Retrieved 8 May 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "Capmatinib". SPS - Specialist Pharmacy Service. 4 July 2020. Archived from the original on 14 August 2020. Retrieved 29 December 2021.
- ^ "Tabrecta Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 29 December 2021.
